Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30266774

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2018 Dec 20
First author
Moskowitz CH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Moskowitz CH
      type
      Author
    2. name
      Walewski J
      type
      Author
    3. name
      Nademanee A
      type
      Author
    4. name
      Masszi T
      type
      Author
    5. name
      Agura E
      type
      Author
    6. name
      Holowiecki J
      type
      Author
    7. name
      Abidi MH
      type
      Author
    8. name
      Chen AI
      type
      Author
    9. name
      Stiff P
      type
      Author
    10. name
      Viviani S
      type
      Author
    11. name
      Bachanova V
      type
      Author
    12. name
      Sureda A
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Moskowitz CH
      type
      Author
    2. name
      Walewski J
      type
      Author
    3. name
      Nademanee A
      type
      Author
    4. name
      Masszi T
      type
      Author
    5. name
      Agura E
      type
      Author
    6. name
      Holowiecki J
      type
      Author
    7. name
      Abidi MH
      type
      Author
    8. name
      Chen AI
      type
      Author
    9. name
      Stiff P
      type
      Author
    10. name
      Viviani S
      type
      Author
    11. name
      Bachanova V
      type
      Author
    12. name
      Sureda A
      type
      Author
    bibliography ids
    1. nci-bib-91b831ae4ce217a085b80cb7
    book metadata
    content sha256
    fe6f6b5fa90fe8c71c0ebec319384c216908e8dcd08159e75ac000b6a676505c
    document type
    citation
    dois
    1. 10.1182/blood-2018-07-861641
    electronic publication date
    display
    2018 Sep 28
    precision
    day
    year
    2018
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:30266774
    immutable id
    pubmed:30266774@fe6f6b5fa90fe8c71c0ebec319384c216908e8dcd08159e75ac000b6a676505c
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    25
    name
    Blood
    nlm unique id
    7603509
    pages
    2639-2642
    volume
    132
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      30266774
      provenance
      batch id
      438b2803888025c6cf56
      provider
      NCBI PubMed ESummary
      record sha256
      7918b9ffa7e29a2a8872c95d4271797d7d04fb718872f27348be67c7ac55ec78
      response sha256
      0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
      retrieved at
      2026-09-09T23:47:36.359220+00:00
      publication date
      display
      2018 Dec 20
      precision
      day
      year
      2018
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/30266774/
      title
      Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

      Preserved source evidence · Not medical advice